Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Core Viewpoint - Savara Inc. has announced that the FDA has filed for review the Biologics License Application (BLA) for MOLBREEVI, aimed at treating patients with autoimmune pulmonary alveolar proteinosis (PAP), marking a significant milestone for both the company and the autoimmune PAP community [1] Group 1 - The FDA has granted Priority Review for the BLA, with a Prescription Drug User Fee Act (PDUFA) action date set for August 22, 2026 [1]